Your browser doesn't support javascript.
loading
Virological characteristics of the SARS-CoV-2 JN.1 variant.
Kaku, Yu; Okumura, Kaho; Padilla-Blanco, Miguel; Kosugi, Yusuke; Uriu, Keiya; Hinay, Alfredo A; Chen, Luo; Plianchaisuk, Arnon; Kobiyama, Kouji; Ishii, Ken J; Zahradnik, Jiri; Ito, Jumpei; Sato, Kei.
Afiliação
  • Kaku Y; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo 113-8654, Japan.
  • Okumura K; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo 113-8654, Japan; Faculty of Liberal Arts, Sophia University, Tokyo, Japan.
  • Padilla-Blanco M; First Medical Faculty at Biocev, Charles University, Prague, Czechia; Departamento de Farmacia, Facultad de Ciencias de la Salud, Universidad Cardenal Herrera-CEU, CEU Universities, Valencia, Spain.
  • Kosugi Y; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo 113-8654, Japan; Graduate School of Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo 113-8654, Japan.
  • Uriu K; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo 113-8654, Japan; Graduate School of Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo 113-8654, Japan.
  • Hinay AA; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo 113-8654, Japan.
  • Chen L; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo 113-8654, Japan; Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan.
  • Plianchaisuk A; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo 113-8654, Japan.
  • Kobiyama K; Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo 113-8654, Japan; International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo 113-8654, Japan.
  • Ishii KJ; Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo 113-8654, Japan; International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo 113-8654, Japan.
  • Zahradnik J; First Medical Faculty at Biocev, Charles University, Prague, Czechia.
  • Ito J; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo 113-8654, Japan; International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo 113-8654, Japan.
  • Sato K; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo 113-8654, Japan; Graduate School of Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo 113-8654, Japan; International Vaccine Design Cente
Lancet Infect Dis ; 24(2): e82, 2024 Feb.
Article em En | MEDLINE | ID: mdl-38184005

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 Idioma: En Ano de publicação: 2024 Tipo de documento: Article